James Commers
Hematology & Oncology · Omaha, NENPI 1871687681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.4% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 82 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$189
- E.r. Squibb & Sons, L.L.C.$167
- Pharmacyclics LLC, An Abbvie Company$119
- Johnson & Johnson$104
- Sanofi$99
- Lilly USA, LLC$94
- plus $639 from 21 others
What the payments were for
- Food & beverage$1,27590%
- Education$13610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 6 | $189 |
| E.r. Squibb & Sons, L.L.C. | 11 | $167 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $119 |
| Johnson & Johnson | 7 | $104 |
| Sanofi | 6 | $99 |
| Lilly USA, LLC | 6 | $94 |
| Merck | 4 | $72 |
| Amgen | 4 | $55 |
| AstraZeneca | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Pfizer | 3 | $43 |
| Genentech USA, Inc. | 2 | $39 |
| Servier Pharmaceuticals LLC | 2 | $33 |
| Tolmar Pharmaceuticals, Inc. | 2 | $33 |
| Rigel Pharmaceuticals, Inc. | 2 | $28 |
| Bayer | 2 | $27 |
| Agios Pharmaceuticals, Inc. | 2 | $27 |
| Novartis | 2 | $27 |
| Blueprint Medicines Corporation | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| GSK | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Morphosys, US Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| AbbVie | 1 | $11 |
How this compares
$1,410 in reported general payments places this provider in the 35th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.